Optune Lua
Novocure, GmbH · Decision date Oct 26, 2026
What did the FDA decide?
The FDA issued a 30-Day Notice decision for Novocure GmbH's Optune Lua (P230042/S010) on October 26, 2026, approving changes to the sterilization load configuration. The supplement type is a 30-Day Notice, and the stated supplement reason is a process change involving the manufacturer, sterilizer, packager, or supplier.
This supplement does not represent a new approval of the entire Optune Lua system or a new indication. The source statement identifies the device category as electrical tumor treatment fields for non-small cell lung cancer, but no clinical effectiveness or safety conclusions are provided in the decision record. Specific details about the exact sterilization load configuration change are absent from the available fields.
FDA approval order statement
approval for changes to the sterilization load configuration.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Anesthesiology
- Decision date
- Oct 26, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230042/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Novocure, GmbH
- Product code
- SDA
- Decision code
- OK30
- Decision date
- Oct 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Electrical tumor treatment fields for non-small cell lung cancer.
- Applicant
- Novocure, GmbH
- Product code
- SDA
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230042. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230042 · Original PMA
Optune Lua
P230042/S010 received
Application receipt date recorded by FDA.
P230042/S010 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optune LuaP230042 | Novocure, GmbH | PMA approval | Oct 15, 2024 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P230042/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records